Lithium is still the main agent in the management of
mood disorders such as depression. Likewise,
agmatine protects the central nervous system (CNS) against depression. The aim of the present study was to examine the possible additive
antidepressant-like effect of
agmatine and
lithium in mice forced swim test (FST) as well as exploration of the probable involvement of
nitric oxide (NO) pathway in this response. Results showed that pretreatment with a subeffective dose of
agmatine (0.01 mg/kg) augmented the
antidepressant-like effect of
lithium subeffective dose (3 mg/kg) (P < 0.001). L-
NG-nitroarginine methyl ester (
L-NAME, nonspecific
nitric oxide synthase [NOS] inhibitor) at doses of 10 and 30 mg/kg, and
7-nitroindazole (7-NI, neuronal NOS inhibitor) at doses of 15 and 30 mg/kg potentiated the
antidepressant-like effect of the subeffective combination of
lithium (3 mg/kg) and
agmatine (0.001 mg/kg) (P < 0.001, P < 0.01, respectively). However, various doses of
aminoguanidine (25 and 50 mg/kg, inducible NOS inhibitor) failed to alter the immobility time of the same combination (P > 0.05). Moreover, pretreatment with subeffective doses of
L-arginine (substrate for NOS, 300 and 750 mg/kg) reversed the augmenting
antidepressant-like effect of
agmatine (0.01 mg/kg) on
lithium (3 mg/kg) (P < 0.001). Our results revealed that
agmatine enhances the
antidepressant-like effects of
lithium and the NO pathway might mediate this phenomenon. In addition, constitutive NOS plays a dramatic role in this response.